A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age /= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Sponsor: |
National Cancer Institute |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS8162 |
U.S. Govt. ID: |
NCT03907488 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and for up to ten years after you stop taking these drugs to treat the cancer.
This study is closed
Investigator
Jennifer Amengual, MD
Are you 12 years of age or older? |
Yes |
No |
Have you been recently diagnosed with advanced stage Hodgkin's Lymphoma? |
Yes |
No |
Are you willing to undergo extra tests and treatment procedures? |
Yes |
No |